Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ARROWHEAD PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for ARROWHEAD PHARMACEUTICALS, INC.

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

About ARROWHEAD PHARMACEUTICALS, INC.

Arrowhead Pharmaceuticals, Inc. is a biotechnology company specializing in RNA interference (RNAi) therapeutics to treat genetic diseases. Its lead candidate, plozasiran, targets familial chylomicronemia syndrome and is set for commercial launch in 2025. With a pipeline of 16 clinical-stage drugs, Arrowhead aims to address previously "undruggable" diseases. The company leverages its proprietary TRiM platform for targeted delivery, focusing on unmet medical needs across various therapeutic areas.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ARROWHEAD PHARMACEUTICALS, INC.

1
1
ARROWHEAD PHARMACEUTICALS, INC. Arrowhead Pharmaceuticals Reports $132.7 Million Net Loss and Revenue Decline in Latest Quarter

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
ARROWHEAD PHARMACEUTICALS, INC. Arrowhead Pharmaceuticals Reports $264M Revenue Growth and Positive Net Income in Latest Quarter

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ARROWHEAD PHARMACEUTICALS, INC. Arrowhead Pharmaceuticals Reports $829.4 Million Revenue Growth and FDA Approval of REDEMPLO

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
ARROWHEAD PHARMACEUTICALS, INC. Arrowhead Pharmaceuticals Reports $27.8M Revenue for Q2 2025, Achieves Net Income of $22.1M for Nine Months

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ARROWHEAD PHARMACEUTICALS, INC. Arrowhead Pharmaceuticals Reports $542.7 Million Revenue in Q2 2025, Significant Profit Turnaround

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ARROWHEAD PHARMACEUTICALS, INC. Arrowhead Pharmaceuticals Reports $173.1 Million Net Loss and Decreased Revenue in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments